2019-2023 Global Bone Cancer Drugs Market Overview

Dublin, May 10, 2019 (GLOBE NEWSWIRE) -- The "Global Bone Cancer Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Small and medium sized pharmaceutical and biotechnology vendors in the bone cancer market face a lack of funding to complete clinical trials and launch drugs for the treatment of various bone cancer indications. Pharmaceutical players face challenges with the distribution of drugs in the regions where the vendor does not operate. To overcome such challenges, these pharmaceutical companies are entering into strategic alliances with local pharmaceutical vendors for the manufacturing and distribution of drugs. The analysts have predicted that the bone cancer drugs market will register a CAGR of nearly 12% by 2023.

Growing risk factors

Growing risk factors associated with bone cancer will drive market growth in the forecast period. The growing prevalence of specific cancers, where radiation therapy has been a dominant treatment, is further stimulating market growth. Factors such as old age and family history of bone cancer are common risk factors for the disease.

Preference of surgery

The most preferred treatment options available to patients with bone cancer, is surgeries, due to their remissive nature. Surgery for bone cancer involves wide excision of the tumor, which includes removal of the tumor along with a part of healthy tissue around the tumor in all directions. The higher probability of recurrence of cancer tumors in the future reduces patient adherence to drug treatment landscape which poses a challenge to the market growth.

Competitive Landscape

The market appears to be concentrated and with the presence of a few companies. Factors such as the growing risk factors and increasing strategic alliances, will provide considerable growth opportunities to bone cancer drugs manufactures.

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY INDICATION

• Market segmentation by indication
• Comparison by indication
• Osteosarcoma - Market size and forecast 2018-2023
• Ewing's sarcoma - Market size and forecast 2018-2023
• Chondrosarcoma - Market size and forecast 2018-2023
• Others - Market size and forecast 2018-2023
• Market opportunity by indication

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

• Market drivers
• Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

• Overview
• Landscape disruption
• Competitive scenario

PART 14: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Amgen
• Bayer AG
• Bristol-Myers Squibb Company
• Merck & Co. Inc.
• Pfizer Inc.

PART 15: APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/gemqj3

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs